Clene Inc.
Clene Inc. (Nasdaq: CLNN) is a clinical-stage pharmaceutical company developing therapeutics using its clean-surfaced nanotechnology (CSN) platform, which produces catalytic nanocrystals and ionic solutions. Its lead candidate, CNM-Au8, is an oral suspension of gold nanocrystals in clinical development for amyotrophic… From the company’s description.
Over the twelve months to Sep 30, 2026, Clene Inc. reported revenue of $0.24M, up 11.2% from a year earlier, and a net loss of $26.83M. Operations used $16.53M in cash. In fiscal 2025, it reported revenue of $0.20M, down 41.5% from fiscal 2024, and a net loss of $26.17M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Clene Inc. does
In the company’s own words
Clene Inc. (Nasdaq: CLNN) is a clinical-stage pharmaceutical company developing therapeutics using its clean-surfaced nanotechnology (CSN) platform, which produces catalytic nanocrystals and ionic solutions. Its lead candidate, CNM-Au8, is an oral suspension of gold nanocrystals in clinical development for amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease; the company’s research also targets other central nervous system disorders. Early-stage assets include CNM-ZnAg and CNM-AgZn17, zinc-and-silver formulations being developed for infectious diseases and, for the topical gel, wound and burn healing. Through its wholly owned subsidiary dOrbital and an exclusive license with 4Life Research, Clene also markets dietary supplements, including rMetx and Gold Factor. Its activities span pharmaceutical research and development, early-stage therapeutic assets and supplement products, rather than reportable operating segments. Clene manufactures its drug candidates and intends to manufacture most or all approved drugs itself. The company reports more than 1,100 participant-years of human exposure to CNM-Au8 as of 2025. Its website is www.clene.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SALT LAKE CITY, UT
- Fiscal year end
- December
- CIK
- 1822791
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Clene Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Clene Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Clene Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Clene Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Clene Inc.'s last four quarterly filings that the numbers alone won't show?”